Exhibit Caution When Interpreting PFS, OS Data in Biosimilarity Studies
September 9th 2017
ArticleOncology trials often report on progression-free survival or overall survival, but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate.